Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole in PPI Failures - IMPROVE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Male or female, aged 18-65 years~* History of GERD symptoms during, at least, six months prior to enrolment~* PPI as maintenance treatment during the last 30 days prior to enrolment~* Heartburn as predominant GERD symptom, as judged by the investigator~* Persisting GERD symptoms during the past 7 days prior to visit 1, judged by the patient as either: 4 days with mild symptoms (i.e. awareness of sign or symptom, but easily tolerated)or 2 days with moderate (i.e. discomfort sufficient to cause interference with normal activities) to severe symptoms (i.e. incapacitating, with inability to perform normal activities)~Exclusion Criteria:~* Any treatment with esomeprazole during 30 days prior to enrolment History of esophageal, gastric or duodenal surgery, except for simple closure of an ulcer~* Current or historical evidence of the following diseases/conditions, as judged by the investigator:Zollinger-Ellison syndrome,Primary esophageal motility disorder, i.e. achalasia, scleroderma, primary esophageal spasm,~* Gastric or duodenal ulcers within the last three months, Malabsorbtion~* Malignancy or other concomitant disease with poor prognosis or which may interfere with the assessments in the study~* Unstable diabetes mellitus. Stable diabetes controlled by diet, oral agents or insulin is acceptable~* Patients with severe diseases or disorders which may interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).